The regenerating liver after partial hepatectomy is one of the few physiologic models of cellular proliferation in the adult animal. During hepatic regeneration, the animal is able to maintain metabolic homeostasis despite the acute loss of two thirds of hepatic tissue. In examining the molecular mechanisms regulating hepatic regeneration, we isolated novel immediate-early genes that are rapidly induced as the remnant liver undergoes the transition from its normal quiescent state into the G1 phase of the cell cycle. One of the most rapidly and highly induced genes which we initially termed RL-1, encodes rat glucose-6-phosphatase (rG6Pase). G6Pase mRNA peaks at 30 min and 36-48 h after hepatectomy correlating with the first and second rounds of cell division. This finding is compatible with studies that showed that G6Pase enzyme activity increases during liver regeneration. However, the increase in G6Pase mRNA is much more dramatic, indicating that it is a more sensitive indicator of this regulation. G6Pase gene expression peaks in the perinatal time period in the liver and remains elevated during the first month of life. The expression of the G6Pase gene is also dramatically elevated in BB diabetic rats, again higher than the enzyme elevation, and its relative induction after partial hepatectomy is blunted in these animals. Insulin treatment of partially hepatectomized diabetic animals downregulates the expression of G6Pase mRNA. Using specific antibodies against G6Pase, we detect a 36-kD G6Pase protein, and its level is elevated in regenerating and diabetic livers. The pattern of G6Pase mRNA expression appears to reflect similar changes in insulin and glucagon levels which accompany diabetes and hepatic proliferation. The elevation of G6Pase expression in these conditions is indicative of its importance as a regulator of glucose homeostasis in normal and abnormal physiologic states. (J. Clin. Invest. 1995. 95:832-841.) 
Introduction
The regenerating liver after partial hepatectomy is one of the few adult organs that demonstrates a physiologic growth re-sponse (1-3). As such it provides an intact animal model in which cellular proliferation can be studied. Within minutes after two thirds partial hepatectomy, the majority of cells in the remnant liver which are normally quiescent rapidly reenter the cell cycle accompanied by the induced expression of a large number of growth response genes. The onset of DNA synthesis occurs at 12-16 h after hepatectomy in hepatocytes with peak level at 24 h, and the mass of the liver is restored within 7-10 d when proliferation ceases. A number of growth factors has been implicated as having a role in this process including HGF, TGFa, insulin, glucagon, and others, but the exact mechanisms regulating this process are unknown. As the liver is a vital organ, it must maintain metabolic and synthetic homeostasis throughout the regenerative period. Studies have shown that there is an acute fall in insulin and an increase in glucagon levels immediately after hepatectomy both of which begin to renormalize within a few hours, thereby preventing the hypoglycemia which might accompany the loss of liver mass (4, 5) . Previously, we and others (6) (7) (8) (9) showed that phosphoenol pyruvate kinase (PEPCK)' and other genes involved in glucose homeostasis are rapidly up-or downregulated in the regenerating liver, thus allowing the remnant liver to maintain glucose balance.
To begin to define the molecular basis for liver regeneration, our laboratory first identified a large number of novel immediate-early genes that are induced in the remnant liver within minutes after partial hepatectomy (10) . In total we have examined the expression of more than 70 immediate-early genes expressed in the regenerating liver. Of these, approximately one third show liver-restricted induction and are not induced in mitogen-stimulated cells such as 3T3 fibroblasts (10, 11 ). One of these, RL-I ( 10, 12, 13) , showed a very high peak of expression within 30 min after hepatectomy and was expressed in a tissue-restricted fashion with highest levels in liver and kidney. As we were particularly interested in defining the liver-specific aspects of cell growth, we focused on the characterization of RL-J. After completing several studies, we found upon a repeat data bank search that RL-l is the rat homologue of the recently identified glucose-6-phosphatase (G6Pase) gene (14) .
G6Pase is a key regulatory enzyme in glucose homeostasis, catalyzing the final step in gluconeogenesis and glycogenolysis (15) . Decreased levels are found in two different diseases. In glycogen storage disease type 1, a mutated form of G6Pase is found ( 16) . In tyrosinemia type 1, toxic by-products secondary to a deficiency of fumaryl acetoactetate result in decreased expression of G6Pase. The mouse model for this form of tyrosinemia has demonstrated that the usual perinatal expression of G6Pase is blunted ( 14, 17) . Purification of G6Pase was difficult because of its tight association with the endoplasmic reticulum 1 2 3 4 6 8 0 1 and nuclear membranes (18) (19) (20) (21) . Using enzymatic assays, G6Pase has commonly been used as a marker for hepatocytes. It is present in the periportal area in normal liver, but dispersed throughout the liver at 4 h after hepatectomy (22) . Its expression in diabetics and its regulation by insulin are complex. G6Pase activity has been reported to be high in diabetic animals (23) (24) (25) , regardless of glycemia (26, 27) , and its activity has been shown to be decreased by insulin and increased by glucagon (28 (10) . RNA was prepared in 4 M guanidine thiocyanate buffer and RNA prepared as described (31) . Diabetic BB rats (300-400 g), aged 3-5 mo, were maintained on 2 U of sc lente (long-acting) insulin daily. Insulin was withheld on the day of surgery when, after ether anesthesia, 70% liver resection was performed as described above. Rats were subsequently killed at different time points, and total liver RNA was prepared. Blood glucose (Accuchek III; Boehringer Mannheim, Indianapolis, IN) and serum insulin levels (RIA assay; Diabetes Center Core, University of Pennsylvania Medical School) were measured preoperatively and at the time of killing.
For fetal liver samples, timed pregnant Fischer female rats were purchased from Charles River Laboratories (Wilmington, MA), and embryos were harvested on the indicated days. Total RNA was extracted from the fetal livers after homogenization in guanidine thiocyanate. Each RNA sample represents more than one fetal liver.
Northern blots. Northern blot analyses and labeling of recombinant RL-J/G6Pase plasmids have been described (10) . Hybridization buffer consisted of 10% dextran sulfate, 40% formamide, 0.6 M NaCl/0.06 M Na Citrate, 7 mM Tris (pH 7.6), 0.8 x Denhardt's solution, and 0.002% heat-denatured, sonicated salmon sperm DNA. Northern blots were hybridized at 42°C for 16 h and washed 2 x 30 min at 60°C in 0.015 M NaCl/0.0015 M Na citrate/0.1% SDS before exposure to film (31) .
Antibodies and immunoblots. Anti-polyclonal rG6Pase antibodies were prepared by Cocalico Biologicals (Reamstown, PA) against bacterially expressed purified denatured rG6Pase peptide (amino acids 238-31 1 ). The peptide was expressed as we have described previously using a PET expression vector system (32) after cloning a PCR-generated fragment in front of the polyhistidine region. The sequence was confirmed. Immunoblots were performed as we have described using a 1:1,000 dilution of affinity-purified anti-G6Pase antisera followed by a Expression of the Glucose-6-Phosphatase Gene 1:10,000 dilution of goat anti-rabbit sera and the chemiluminescence detection system (Amersham Corp., Arlington Heights, IL) (33) . Affinity-purified a-G6Pase was prepared on an affigel column using immobilized G6Pase peptide and showed enhanced anti-G6Pase activity.
Cell extracts. Liver was extracted and fractionated as described (34). Nuclei preparation was verified by microscopy, as we have done previously (34, 35) , and was 99% pure. Cytoplasmic material was further fractionated by a high speed ( 100,000 g) spin, followed by resuspension of the pellet in 0.5% Triton, and resuspension of the final Triton-insoluble pellet in loading buffer. Nuclear material was further fractionated by treatment of intact nuclei in 0.5% Triton to remove the outer nuclear membrane, lysis of nuclei by dounce homogenization, and recovery of nuclear extract. The nuclear extract was subjected to high speed centrifugation, the pellet resuspended in 0.5% Triton to recover the Triton-soluble fraction, the Triton-insoluble pellet, and the remaining insoluble material resuspended in loading buffer.
cDNA cloning and DNA sequencing. The G6Pase(RL-J) cDNA was isolated as we have described from a cDNA library prepared from regenerating rat liver at 3 h after hepatectomy following pretreatment with cycloheximide (10) . Several different cDNAs were isolated. The near full-length cDNA copy was verified by primer extension analysis. DNA sequencing was performed bidirectionally using the oligonucleotide primer extension modification of Sanger dideoxy methodology (36 Immunohistochemistry. Immunohistochemistry was performed essentially as has been described (33, 38 (14) (Fig. 2) .
At the time of submission of this manuscript, Lange et al. (41) presented a partial rat G6Pase cDNA sequence and a protein alignment that indicates that G6Pase is highly conserved between human, rat, and mouse. In addition to agreeing with their comments, we note that amino acid residues that are common between two species are different in the third species indicating divergent evolution. The rat G6Pase sequence presented by Lange et al. (41) appears to contain a variant or artifact at amino acid 118, because our sequence indicates that this residue is a glycine, not a valine, the same sequence found at this position in the human and mouse sequences. Unlike the protein sequence, the 3' untranslated regions are relatively nonconserved, even between rat and mouse cDNAs.
The 1 10-bp insert found in the majority of the rat G6Pase cDNA clones corresponds to exon 2 of the mouse G6Pase gene, and the shorter rat cDNA clone could represent an alternatively spliced derivative that is missing this exon. The absence of the exon 2 sequence results in a protein that would be truncated after 137 amino acids due to the initial frame shift and downstream stop codon. In vitro translation of the exon 2 minus synthetic mRNA did not yield a protein product (data not shown). To determine whether this splice variant is present in cells or is an artifact of the cDNA library, we performed RT-PCR of RNA samples prepared from livers at different times after hepatectomy. We found that the exon 2 minus form is present at 20% the frequency of the larger message (Fig. 3 ).
There is no consistent variation in the relative frequency of the two messages during the time course of liver regeneration, and, therefore, there is no reason to suspect that G6Pase levels are regulated by splicing after hepatectomy.
G6Pase mRNA levels are high in the developing and diabetic liver, and insulin downregulates its expression. It is known that G6Pase levels are low until approximately the time of birth when they increase (14) . Thus, it is a late marker of differentiation in the developing liver and reflects the need of the newborn animal for glucose production. We examined the profile of expression of G6Pase mRNA in embryonic and newborn rats and found that the level of G6Pase mRNA increases abruptly at embryonic day 21 and continues to be elevated above adult levels until 4 wk after birth (Fig. 4) . This suggests that the mechanism by which G6Pase gene expression is activated in the perinatal time period may involve hormonal changes that occur just before birth when insulin levels fall and glucagon levels increase (42) .
G6Pase is involved in glucose homeostasis, and in the diabetic animal its basal level is elevated (25, 26) . We examined alterations of G6Pase gene expression after partial hepatectomy in BB diabetic rats as compared with normal animals. The metabolic profile of the animals studied is provided in Table I . We found that G6Pase mRNA is consistently elevated in diabetic animals and that after hepatectomy the relative induction of G6Pase mRNA is blunted in the diabetic animals (Fig. 5 A) . After normalization to the control gene, ATP synthase, the relative induction in the diabetic animals was 1.4 as compared with -25-30-fold for the normal animals. The level of G6Pase mRNA at 1 h after hepatectomy in the normal and diabetic animals was approximately equal because of the elevation in the diabetic animals before hepatectomy. At 8 h after hepatectomy, the G6Pase level has normalized in normal animals but continues to be elevated in diabetics. To determine if the continued expression of G6Pase after hepatectomy in diabetic animals is due to insulin deficiency, we gave insulin to a cohort of diabetic animals at 4 h after hepatectomy and obtained liver and serum samples at 8 h after hepatectomy. These studies were complicated by the fact that the pretreatment level of G6Pase mRNA could not be measured in any individual animal, and thus several animals were studied to provide sufficient data to draw conclusions. In diabetic animals in which glucose, insulin, and PEPCK mRNA levels had normalized by 8 h after hepatectomy following insulin treatment, the level of G6Pase mRNA had also normalized (Fig. 5 B) . However, in animals in which glucose, insulin, and the level of expression of PEPCK (Chin, S., unpublished data) were not corrected by insulin treatment, G6Pase mRNA also remained uncorrected.
The highest specific activity of G6Pase protein and enzymatic activity is found in the nuclear membrane, and the level is elevated in diabetes and regenerating liver. Based on the G6Pase gene expression, we predicted that G6Pase protein and enzymatic activity should be high in regenerating and diabetic liver. It was important to document a correlation between protein and mRNA levels using antibody and enzymatic studies. We raised specific antisera to a nonhydrophobic region of the protein expressed in bacteria. As shown (Fig. 6 A) , these antisera are specific for the peptide, and affinity purification demonstrates enhanced activity. In total cellular immunoblots, G6Pase protein was not detected above the background levels, so subcellular fractionation was performed. G6Pase is a marker for cellular microsomes, but when nuclear/cytoplasmic fractionation is performed much of the activity is associated with nuclear membranes (21). This is not surprising since the endoplasmic reticulum forms a continuum with nuclear membranes. On immunoblots, a single band with a molecular mass of 36 kD is de- tected in the nuclear membrane fraction of the cell. The level of this protein is fourfold higher in the sample prepared at 2 h after hepatectomy than in normal liver (Fig. 6 B, right) . This protein band correlates with the known cellular localization of G6Pase, its molecular mass, and its induction profile in the regenerating liver. To assess the correlation between protein and enzymatic levels, enzymatic assays were performed on the same fractions. The Triton-soluble nuclear fraction had the highest specific activity. However, as nuclear membranes represent only 3% of total cellular protein, total enzyme activity was highest in the Triton-soluble cytoplasmic fraction. G6Pase was not detectable by immunoblot in this fraction because G6Pase represents a smaller percentage of the cytosolic membrane proteins. The relative induction of G6Pase is most apparent in the nuclear membrane fraction (Fig. 6 C, fraction E) where it is induced by more than fivefold, similar to the induction observed on immunoblot.
We also analyzed the tissue distribution of G6Pase by enzymatic and immunohistochemistry on tissue sections obtained from regenerating and diabetic livers (Fig. 7) glucagon change in the same direction but to a lesser extent than after partial hepatectomy (4, 5) . These hormonal changes may contribute to this upregulation. Likewise, an increased glucagon to insulin ratio is seen in diabetes (43) . Increased hepatic glucose production is the major cause of fasting hyperglycemia in all forms of diabetes. Diabetes increases the level of G6Pase activity in the liver while decreasing glucokinase resulting in a net increase in glucose production by the liver. Euglycemic clamp studies suggest that G6Pase levels are downregulated at least in part by the direct effect of insulin (26) . Studies in FAO rat hepatoma cells suggest that G6Pase mRNA is induced by dexamethasone, dominantly downregulated by insulin, and modulated upwards in the presence of cAMP (glucagon mediator) (41) . Our studies are compatible with these findings. Hepatic G6Pase mRNA is grossly elevated in all of the diabetic animals we have tested. After partial hepatectomy in these diabetic animals, the normal induction of this gene is relatively blunted, and the rapid fall in the expression of this gene by 8 h after hepatectomy is abolished. Insulin treatment can normalize the expression of the G6Pase gene in the posthepatectomy time period. Euglycemic clamp studies in diabetic animals will help establish if G6Pase mRNA levels can be corrected after insulin treatment when no surgery has been performed. PEPCK and IGFBP-J are known to be controlled at the level of transcription by insulin (downregulation), glucagon/cAMP (upregulation), and glucocorticoids (upregulation). The expression patterns of the G6Pase gene predict that it may be similarly regulated (10, 33, 44) .
Our studies provide initial evidence that the levels of G6Pase protein and enzyme activity closely follow the mRNA levels in the various physiologic and pathophysiologic conditions we have studied. G6Pase mRNA levels appear to provide a much more sensitive measure of changes in hormonal milieu, as they vary > 20-fold as compared with a fewfold in protein or enzyme levels. However, measurement of protein is a valuable means of assessing the activity and localization of the enzyme, and the feasibility of immunoblot and immunohistochemistry analyses has now been established.
These studies also shed some light on insulin's role during liver regeneration. The effects of insulin on the mitogenesis of hepatic cells suggest that insulin can be a potent growth factor mediated through the insulin receptor (45) . In diabetic animals, regeneration is delayed or absent as determined by thymidine incorporation, and this effect can be restored by insulin administration (46). In addition to its proposed mitogenic role, insulin clearly has a metabolic role in liver growth. The acute fall in insulin levels within minutes of the surgery is important for allowing maintenance of normal glucose levels. Since insulin levels return toward a normal level after the first few hours (4, 5) after hepatectomy, it seems likely that, if insulin has a mitogenic as well as metabolic effect during regeneration, it would occur in mid to late GC. However, the importance of insulin in maintaining the metabolic and nutritional homeostasis of the animal makes it difficult to determine from these studies if insulin has a mitogenic effect in hepatic regeneration. Insulinopenic or diabetic animals would likely have metabolic abnormalities that could secondarily prevent normal cellular proliferation.
